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dergoing transcatheter aortic valve replacement, elevated neutrophil
to lymphocyte ratio was associated with increased mortality at 30
days. This effect was independent of previously established risk
predictors in these patients. More large scale randomized studies are
needed to further evaluate these results.
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BACKGROUND Transcatheter aortic valve-in-valve (ViV) implantation
inside failed bioprostheses is an alternative approach to repeat open
heart surgery for those with failed bioprosthetic valves. However,
stentless surgical valves lack ﬂuoroscopic markers and provide
distinctive challenges. Our objective was to compare clinical out-
comes following aortic ViV procedures in stentless vs. stented bio-
prostheses, using a large global registry.
METHODS A total of 1,104 aortic ViV procedures from the ViV Inter-
national Data (VIVID) registry were investigated (903 stented bio-
prostheses, 201 stentless).
RESULTS Patients with stentless bioprostheses were younger and had
similar STS risk of mortality scores when compared to their stentedcounterparts (74.7 12.4 vs. 78.68 8.3, p< 0.001; 9.8 8.4 vs. 10.5 9.3,
p¼0.41, respectively). Stentlessbioprostheseshada longermedian time to
failure and failed predominantly with regurgitation (12 vs. 9 years, p <
0.001; 57.6%vs. 25.6% regurgitation, p<0.001, respectively). The effective
oriﬁce area was larger in stentless valves than in stented ones (valve area
1.2  1.5 vs. 0.94  0.6 cm2, p ¼ 0.02, respectively), with smaller mean
gradients as well (27.1 vs. 37.63 mmHg, p < 0.001, respectively). Stentless
bioprostheses were more commonly treated with self-expandable devices
(66.8% vs. 54.5% of stented, p < 0.001) and transesophageal echocardi-
ography was more commonly utilized in these procedures (73.1% vs.
56.4%, p < 0.001). Device malposition was more common in stentless and
Mosaic surgical valves than in stentednon-Mosaicones (12.3%vs. 12.4%vs.
5.1%, p < 0.001, respectively). There was a greater need for second trans-
catheter heart valve device in stentless valves as well (8.5% vs. 3.6%, p ¼
0.002). Coronary obstruction was more common in stentless valves (5.8%
vs. 1%,p<0.001). Final aortic valve areawasgreater in stentlessprostheses
(1.75  0.4 vs. 1.41  0.6 cm2, p < 0.001) and post-procedure mean gradi-
entswere also lower in this group (11.7 7 vs. 17.2 9.6mmHg, p< 0.001).
There was a trend towards higher 30-day mortality in stentless valves
(8.4%vs. 5%, p¼ 0.07). However, 1-yearmortalitywas similar between the
groups (14% stentless vs. 16.6% stented, p ¼ 0.59).
CONCLUSIONS Aortic ViV procedures inside stentless bioprostheses
are challenging and associated with more device malposition, coro-
nary obstruction and a trend towards increased short-term mortality.
However, stentless ViV procedures offers improved hemodynamics
with similar survival rates at one year.
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BACKGROUND The latest generation of the balloon-expandable
Edwards SAPIEN device, the SAPIEN 3, has shown very positive re-
sults in recently published studies. Most notably, it demonstrated a
low rate in paravalvular regurgitation, a low rate in vascular access
site complications, a low stroke rate and a very low mortality rate.
These clinical outcomes are mainly due to signiﬁcant design im-
provements: downsizing of the delivery system (Edwards Commander
delivery system) with sizes of 14F (23 mm and 26 mm device) and 16F
(29mm device) and a paravalvular sealing cuff to reduce the amount
of residual paravalvular regurgitation. According to these changes,
new sizing recommendations were developed for the SAPIEN 3 device,
which even allows slight undersizing.
METHODS To analyze the percentage of patientswho couldhave received
a SAPIEN 3 device in a transfemoral TAVR patient cohort. We retrospec-
tively reviewed CT-scans of 201 TAVR patients implanted between
February 2014 (when the SAPIEN 3 was introduced at our hospital) and
April 2015 and compared the suitability for the SAPIEN 3 and SAPIEN XT
respectively, based on access vessel and/or the 3D annulus diameter.
RESULTS With respect to the new sizing guidelines for the SAPIEN 3,
196 patients (98%) of the 201 patients analyzed would have been suit-
able for an implantation with the new SAPIEN 3 device. In contrary, the
SAPIEN XT device could have been implanted in signiﬁcantly less pa-
tients (80%). The SAPIEN 3 device was ﬁnally implanted in 102 patients
(52%). The short-term outcome of this cohort showed excellent results.
Paravalvular regurgitation was virtually absent with the vast majority
having none or trace postinterventional aortic regurgitation on echo-
cardiography (90.7%). None of the patients had more than mild para-
valvular regurgitation. Major vascular access site complications or
major bleeding according to the VARC II criteria were not observed in
our cohort. Minor vascular complications and minor bleeding occurred
in 6.8 % and 3.9 % respectively. If vascular complication occurred, they
were related to closure device failure with subsequent stent graft im-
plantation. Thirty-day outcome showed a very low major stroke rate
(1.9%) and a low mortality rate (2.9%). However, we observed a 20.6%
permanent pacemaker rate in our SAPIEN 3 cohort.
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and changes in the 3D sizing guidelines, the new third generation
SAPIEN 3 device can be implanted in the majority of TAVR patients.
Thus, signiﬁcant more TAVR patients can beneﬁt from an aortic valve
replacement with the new SAPIEN 3 device. Within our cohort, im-
plantation of the new SAPIEN 3 device resulted in excellent proce-
dural and short-term outcomes.
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BACKGROUND Transcatheter aortic valve implantation (TAVI) has
been worldwide adopted, but there are still several areas where
consensus and evidence are lacking. Pre-procedural work-up process
is essential to determine eligibility and predict outcomes, but may
vary across centers. The objectives were to determine the real life
practice related to pre-procedural TAVI planning across different
centers around the world.
METHODS From January to May 2015, an online survey was distrib-
uted worldwide in centers performing TAVI regardless the number of
procedures and valve type. There was a responsible to distribute the
survey for each country or region.
RESULTS A total of 167 centers (including 37843 TAVI procedures)
responded the questionnaire from 27 different countries in Europe,
North-America and South-America. Heart team meetings were regu-
larly scheduled in most of the centers (>95%) with high participation
of interventional cardiologist (95%) and cardiac surgeon (94%), but
low involvement of other specialists (radiologists 16%; internists/ge-
riatrics 14%). While one or two surgical risk scores were used in 99%
and 65% of the centers, respectively; frailty (37%), quality of life (23%)
or 6 minute walking (3%) assessments were rarely performed. Mod-
erate or low risk patients represent 20% of the TAVI candidates.
Cardiac-CT was the preferred imaging study for annulus measure-
ments and valve sizing (87%). Finally, concomitant severe coronary
artery disease (CAD) was treated before or during the TAVI procedure
in 79% and 4% of centers, and 3% of centers did not treat systemati-
cally signiﬁcant CAD in TAVI candidates.
CONCLUSIONS In the real-world practice, up to one-ﬁfth of patients
undergoing TAVI are considered at moderate or low surgical risk.
While the role of the Heart Team on the clinical-decision making
process is well established, the involvement of other non-cardiovas-
cular specialists remains anecdotic. Cardiac CT scan is the “gold
standard” for annulus assessment and valve sizing, and signiﬁcant
CAD is treated before the TAVI procedure in the majority of centers.
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BACKGROUND Higher calciﬁcation of the aortic valve complex in-
creases the risk of post-dilatation and paravalvular leak (PVL) after
transcatheter aortic valve replacement (TAVR). The role of aggressive
oversizing as a predictor of PVL post TAVR is not well understood. The
aim of this study was to evaluate the association between degree of
aortic valve complex calciﬁcation and PVL after aggressive oversized
balloon-expandable TAVR.
METHODS Between January 2013 and April 2015, a total of consec-
utive 347 patients with severe aortic stenosis underwent TAVR
(Sapien¼70 or XT¼270) and had suitable contrast cardiac CT.
Aggressive oversizing was deﬁned as over 20% of area oversizing. A
region of interest for calcium volume included the total leaﬂet re-
gion - the area from the annulus to leaﬂet tips and left ventricular
outﬂow tract (LVOT) region- the area from the annulus to 5 mm
inferior to it. Annular device landing zone (ALZ) consisted of the
area from the annulus to 3 mm superior to it and 2 mm inferior to
it. Aortic valve complex was also divided by each leaﬂet sector.
Calcium (CA) scoring was set at 850 Hounsﬁeld Unit threshold. Post
procedural PVL was evaluated by transthoracic echocardiography at
30days.
RESULTS Of 347 patients, aggressive oversizing was performed in133
patients (38.3%). From these patients, 31 patients (23.3%) had
PVL mild (25 patients) or moderate PVL  (6 patients). One patient
had aortic annulus injury. Mean total leaﬂet CA, ALZ CA, and LVOT CA
were 160.9 mm3, 24.2mm3, and 0.4mm3, respectively. ALZ CA, left
coronary cusp (LCC)-ALZ CA, and LCC-LVOT CA were higher in PVL
(41.8  49.7 mm3 vs. 18.9  30.4 mm3; p¼0.02, 22.1  28.8 mm3vs. 8.5
 16.6 mm3; p¼0.016, 17.3  24.3 mm3 vs. 6.0  21.7 mm3; p¼0.025,
respectively). In receiver operator characteristic curve analysis, LVOT
CA and LCC-LVOT CA were predictor of PVL (area under the curve
(AUC) ¼0.739; 95% conﬁdence interval (CI) 0.638-0.840; p <0.001,
AUC¼0.704; 95% CI 0.592-0.816; p¼0.001, respectively).
CONCLUSIONS Of aortic valvular complex calciﬁcation, LVOT volume
was the strongest predictor for PVL after aggressive oversizing
balloon-expandable TAVR.
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BACKGROUND Transcatheter aortic valve replacement (TAVR) en-
ables treatment of inoperable and high risk patients with severe aortic
stenosis. Impact of concomitant mitral regurgitation (MR) on outcome
in patients undergoing TAVR appears to be unclear. Therefore, it was
aim of this study to evaluate the impact of MR on outcome after TAVR.
METHODS Patients with severe aortic stenosis, in which TAVR was
performed between 2006 and 2014 were included into the analysis.
MR was measured by echocardiography at baseline, 30 days and at
one year, 30-day and 1-year mortality was calculated.
RESULTS Between January 2006 and May 2014 a total of 1530
consecutive patients (Age 80.35.9 years, Logistic EuroScore 2013%,
STS PROM 8.56.2%) with severe aortic stenosis were treated with
TAVR at our institution. At baseline 178 (10.3%) of these patients
presented with no MR, 1173 (68.2%) with mild MR (grade 1), 171 (9.9%)
with moderate MR (grade 2) and 9 (0.5%) with severe MR (grade 3).
Patients with moderate to severe MR showed signiﬁcantly higher
